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Abstract 
Cardiovascular diseases (CVDs) are the leading cause of death 
worldwide. A number of comorbidities are associated with CVDs and 
prognosis is poor, with many patients experiencing disease progression. 
Recognizing the factors associated with CVDs progression enables high risk 
patients to be identified and given more intensive treatment if necessary. The 
identification of new predictive markers might improve the understanding of 
the pathogenesis and progression of CVDs. This study discusses a 
comparison between heart-type fatty acid-binding protein (H-FABP) and 
asymmetric dimethylarginine (ADMA) as a risk marker by induction 
cardiovascular problems in male adult albino rats by exposing to acute 
Carbon monoxide (CO) poisoning. CO intoxication causes cardiovascular 
problems as a result of diffuse tissue hypoxia. The rats were exposed to a 
mixture of either 3000 (group A) or 5000 (group B) parts per million (ppm) 
CO in air, or to ambient air (group C, control group). Blood samples were 
taken just before, immediately after and 6 hours after the exposure, and 
serum H-FABP and ADMA levels were measured. Serum H-FABP levels 
increased just after the CO exposure in both groups A and B. Additionally, 
H-FABP level was higher in group B than in group A, immediately after the 
exposure. However, plasma ADMA levels only increased at 6 hours after the 
CO exposure in groups A and B. The study results suggest that H-FABP 
might have potential to be an early and quantitative parameter of clinical 
severity and prognosis in CVDs. 
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Introduction 
Cardiovascular diseases (CVDs) are the leading cause of death 
worldwide. People of all ages and backgrounds can get the condition. About 
600,000 people die of heart disease in the United States every year–that’s 1 
in every 4 deaths (Kochanek et al., 2011). Every year about 715,000 
Americans have a heart attack. Of these, 525,000 are a first heart attack and 
190,000 happen in people who have already had a heart attack (Finegold et 
al., 2012 and Go et al., 2013). Knowing the warning signs and symptoms of 
a CVDs is key to preventing death, but many people don’t know the signs, so 
there is an urgent need to develop a new risk marker for CVDs. 
Heart-type fatty acid-binding protein (H-FABP) is a low-molecular-
weight protein found in the cytoplasm of cardiac myocytes at high 
concentrations in comparison with other human cells (Valle et al., 2008). As 
myocardial cell membrane is damaged by ischemia, H-FABP leaks to the 
extracellular space and enters the blood circulation very easily and quickly 
due to its small size and water solubility. Owing to its early elevation, it is 
suggested that H-FABP maybe a useful tool in the early assessment of acute 
coronary syndrome (Okamoto et al., 2000 and Nakata et al., 2003).  
Asymmetric dimethylarginine (ADMA) is a naturally occurring 
chemical found in blood plasma. It is a metabolic by-product of continual 
protein modification processes in the cytoplasm of all human cells. It is 
closely related to L-arginine, a conditionally essential amino acid. ADMA 
interferes with L-arginine in the production of nitric oxide, a key chemical to 
endothelial and hence cardiovascular health so it is conceder as an important 
marker of cardiovascular disease (Böger et al., 2000; Krzyzanowska et al., 
2006; Meinitzer et al., 2007 and Edrees, 2010). 
The clinical profile is the most important factor in making decisions 
about the treatment of CVDs patients (Fuster et al., 2010 and Mendis et al., 
2011). Currently, myocardial injury is determined by elevation of cardiac 
enzymes and ischemic electrocardiography (ECG) changes in the clinical 
practice. However, due to their comparatively late elevation, the cardiac 
enzymes may cause the delay in the assignment of strategy for the treatment. 
Therefore, an early biochemical marker that would help to evaluate the 
severity of CVDs and to decide the management strategy is needed. The aim 
of this study was to compare between the serum H-FABP level and plasma 
ADMA in the early period of CVDs as a risk marker of cardiovascular 
diseases in rats. 
 
Material and Methods  
I-Material 
This study was carried out on male albino rats Rattus rattus as an 
animal model for induction of CVDs. 30 young adult male albino rats were 
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employed in the current study. They were obtained from the Serum and 
Antigen Laboratories at Helwan with an average weight of 120±10 g 
representing 10 ± 1 weeks of age. Animals were allowed ten days pre-
experiment period to adapt to laboratory conditions in order to avoid any 
complications along the course of' the experiment. They were housed in 
metallic cages at 28±20C and 50% relative humidity and received food and 
water ad-libitum with fresh supplies presented daily. 
 
II-Methods  
Rats were anesthetized (100 mg/kg ketamine and 0.75 mg/kg 
chlorpromazine; intraperitoneally [i.p.]) and right jugular vein was 
catheterized for blood sampling. The venous catheter was tunnelled 
subcutaneously and externalized at the nape of the neck for access during 
blood sampling. After surgery, rats were housed individually, with free 
access to food and water during the 48-hours recovery period before 
commencing the experiments. 
The rats were exposed to a mixture of either 3000 (group A, n = 12) 
or 5000 (group B, n = 12) ppm CO in air or to ambient air (group C, control 
group, n = 6) at a rate of 4 L/min for 30 min in 16-L Plexiglas chamber.14 
Blood samples were taken just before, immediately after and 6 hours after 
the exposure to either CO or ambient air. Blood samples were separated into 
two batches of blood samples (with or without heparin as anticoagulant) 
were collected from each rat on each time interval. Serum and plasma were 
separated and divided into considerable aliquots to avoid the effects of 
repeated thawing and freezing. All specimens were stored at – 20°C until 
use. The level of consciousness was evaluated by testing the response of rat 
to painful stimulus (pricking the rat’s sole) at the end of the CO exposure,14 
and the rate was monitored for 7 days. 
 
Biochemical methods: 
The serum H-FABP levels were measured by enzyme-linked 
immunosorbent assay with commercially available kits (Life diagnostic, Inc., 
West Chester, Pennsylvania, USA); while Plasma ADMA was determined 
using commercial kits purchased from American Laboratory Products 
Company (Alpco Diagnostics), USA and according to the method of Schulze 
et al., 2004. In addition, blood samples taken just after the CO poisoning 
were also analyzed for carboxyhemoglobin (COHb) levels. Blood COHb was 
measured by using Roche OMNI S Blood Gas Analyzer (Roche Diagnostics 
Inc, Indianapolis, Indiana, USA). 
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Statistical analysis: 
All data are expressed as means + S.E. Following the assurance of 
normal distribution of biochemical data (i.e. serum levels of H-FABP and 
plasma levels of ADMA), repeated measures analysis of variance (ANOVA) 
was used to evaluate the effect of time for each group. The comparisons 
between groups within a time point were evaluated with Student’s t test. The 
results of the consciousness and survival rates were analyzed using two-
tailed Fisher’s exact tests. Differences were considered statistically 
significant if p < 0.05. All Statistical analyses were performed using the 
SPSS 15.0 software. 
 
Results 
Blood COHb levels just after the CO poisoning were higher in group 
A (41% ± 2.5 %, p < 0.01) and group B (59 ± 5.1 %, p<0.01), compared to 
group C (0.4% ± 0.2%). Additionally, COHb level was higher in group B 
than in group A (p < 0.01). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Serum H-FABP levels before, immediately after and 6 hours 
after the CO exposure. 
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Figure 1 shows serum H-FABP levels in group A (3000 ppm CO 
exposure), group B (5000 ppm CO exposure) and group C (ambient air 
exposure) at different time points. In group C, serum H-FABP levels did not 
change along the study period (6 hours). Serum H-FABP levels acutely 
increased just after the CO exposure in both group A (p< 0.001) and B (p< 
0.001), compared to pre-exposure. At 6 hours after the exposure, although 
there was a marked reduction, H-FABP levels were also higher in groups A 
(p< 0.05) and B (p< 0.05), compared to pre-exposure.  
Figure 2 shows plasma ADMA levels in three groups at different 
time points. Plasma ADMA levels had slight changed just after CO exposure 
in either group A or group B, compared to pre-exposure but not significant 
statistically. At 6 h after the exposure, ADMA levels were high in group A (p 
< 0.01) and B (p < 0.001), compared to pre-exposure.  
 
Discussion 
Egyptians are most vulnerable to heart diseases at an early age. The 
possible causes of this increase are the progressive ageing of the population, 
urbanization, dietary changes, sedentary lifestyles, smoking and stress 
(Alexandria conference, 2013). This study discusses a comparison  between 
H-FABP and ADMA as a risk marker by induction cardiovascular problems 
in male adult albino rats by exposing to acute carbon monoxide (CO) 
poisoning. CO  intoxication causes cardiovascular problems as a result of 
diffuse tissue hypoxia. So, the rats were exposed to two different doses of 
CO (3000 and 5000 ppm) in air. In both groups, H-FABP levels significantly 
increased immediately after CO exposure and, although it was relatively 
decreased, remained high at 6 hours after the exposure. On the other hand, 
Figure 2. Plsma ADMA levels before, immediately after and 6 h after 
the CO exposure. 
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ADMA levels only increased at 6 hours after poisoning in both groups. 
These results show that serum level of H-FABP increases in early phase of 
acute CO poisoning prior to ADMA in rats. When it was assessed with 
respect to different CO doses, H-FABP level was higher in the high-CO 
group than that in low-CO group immediately after the exposure. It appears 
that the increased H-FABP concentrations are related to severity of CO 
poisoning which indicate to CVDs. These results suggest that serum H-
FABP level is related with the clinical profile and prognosis in CVDs in rats.   
The pathological changes associated with CO poisoning are mainly 
related to CO-induced hypoxia. CO binds rapidly to hemoglobin, leading to 
the formation of COHb, and the oxygen carrying capacity of the blood 
decreases, causing tissue hypoxia (Prockop and Chichkova, 2007). Elevated 
COHb measurements are used to confirm a clinical diagnosis of exposure to 
CO and, in some instances, assess the severity of poisoning (Ernst and 
Zibrak, 1998). In current study, blood COHb levels increased after CO 
exposure in both groups, and COHb level was higher in high-CO group than 
in low-CO group. 
It is suggested that patients vulnerable to CVDs should be screened 
for myocardial injury (Henry et al., 2006). Tissue hypoxia in CO poisoning 
is often responsible for cardiac damage that is not always registered in ECG 
recordings. Therefore, it maybe necessary to look for other indicators such as 
biochemical markers (Hampson and Hauff 2008). The molecule of H-FABP 
is smaller than that of myoglobin, ADMA and creatine kinase isoenzyme 
MB (CK-MB), permitting it leak from damaged cardiomyocyte earlier. At 15 
min after acute myocardial infarction in rats, plasma concentration of H-
FABP was found to be four times higher than that of the baseline level 
(Aslan et al., 2006). Moreover, a significant correlation was found between 
the amount of released H-FABP and the infarct size in humans and mice, 
which maybe helpful in anticipation of infarction prognosis clinically (Glatz 
et al., 1994 and Meng et al., 2006). These results showed that serum level of 
H-FABP increases in early phase of the acute CO poisoning prior to ADMA 
in rats (Lajer et al., 2008). Additionally, H-FABP, but not ADMA, level was 
higher in the high-CO group than in the low-CO group immediately after the 
exposure. These results suggest that H-FABP is an acute reactant and a more 
sensitive marker than ADMA in CVDs in rats.  
 
Conclusion 
In conclusion, our results suggest that increased serum H-FABP 
levels are associated with CVDs in rats. This result also indicates that H-
FABP might have a potential to be an early and quantitative parameter of 
clinical severity and the prognosis in CVDs. This study now needs to be 
supported by further experimental and clinical studies.  
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